Malaria Vaccine Market Report 2025 (Global Edition)

Global Malaria Vaccine Market Report 2025 Market Size Split by Agent (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species), by Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Other...

Malaria Vaccine Market Report Description

We have various report editions of Malaria Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Malaria Vaccine Market Insights Video

Competitive Landscape of the Malaria Vaccine Market

In the Malaria Vaccine market's competitive landscape, numerous key competitors are driving innovation and growth. As global interest in malaria eradication continues to grow, key players are well-positioned to make substantial contributions to the market. There is a growing focus on developing next-generation malaria vaccines utilizing new technologies, such as mRNA platforms and viral vector systems. These innovations aim to enhance efficacy, reduce production costs, and improve the stability and delivery of vaccines.

In October 2021, Sanaria Inc., a biotechnology firm, and the Seattle Children's Research Institute recognized as one of the top children's hospitals in the U.S., announced a collaboration agreement focused on the development and commercialization of next-generation PfSPZ vaccines that have been genetically engineered for attenuation. The Sanaria PfSPZ Vaccine and the Sanaria PfSPZ-CVac vaccine have demonstrated 100% protective efficacy against controlled human malaria infections caused by highly variant Plasmodium falciparum (Pf) parasites. Notably, these vaccines have also shown effectiveness in protecting against Pf infections in several trials conducted in Africa. (Source: https://sanaria.com/2021/10/19/sanaria-inc-seattle-childrens/ )

Top Companies Market Share in Malaria Vaccine Industry: (In no particular order of Rank)

• Actiza Pharmaceutical Private Limited (India)
• AdvaCare Pharma (U.S.)
• Ipca Laboratories Ltd. (India)
• Bliss GVS Pharma Ltd. (India)
• GeoVax (U.S.)
• Sumaya Biotech (Germany)
• VLP Therapeutics (U.S.)
• OSIVAX (France)
• AJANTA PHARMA (India)
• Strides Pharma Science Limited (India)
• Mylan N.V. (U.S.)
• Zydus Cadila (India)
• Cipla Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Sanofi (France)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Taj Pharmaceuticals Limited. (India)
• Lupin (India)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Malaria Vaccine Market

Which Region Dominates the Malaria Vaccine Market in 2024?

According to Cognitive Market Research, North America currently dominates the Malaria Vaccines market, and the region is expected to have significant growth during the projected period. As malaria continues to present significant health challenges, particularly in endemic regions, awareness in North America regarding the disease's impact on global health is increasing. From January to December 2023, a total of 68 imported malaria cases were reported in Pima, Arizona (18 cases), San Diego, California (27 cases), and El Paso, Texas (23 cases). This marks a notable increase from 2022, which saw only 28 cases (three in Pima, 12 in San Diego, and 13 in El Paso). Among the 68 imported malaria cases identified in 2023, 15 (22%) involved U.S. residents, two (3%) involved newly arrived refugees, 49 (72%) were among other newly arrived migrants (such as asylum seekers), and two (3%) involved travelers of unknown immigration status. Initiatives by organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have played a crucial role in raising awareness about malaria's prevalence and the necessity for effective vaccines.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Governments throughout the Asia Pacific region are enacting national malaria control programs aimed at decreasing the incidence and mortality rates associated with malaria. The Government of India has made a robust commitment to achieving the Sustainable Development Goals (SDGs), particularly SDG 3: “Good Health and Well-Being,” which includes the specific target 3.3 focused on “ending malaria” by 2030. Furthermore, India has pledged to eliminate malaria in the Asia Pacific region by 2030, endorsing the World Health Organization (WHO) Global Technical Strategy (GTS) for Malaria 2016-2030 and the Asia Pacific Leaders Malaria Alliance (APLMA) Roadmap for Malaria Elimination. Additionally, India is a signatory to the 2017 ministerial declaration aimed at accelerating and sustaining malaria elimination efforts in South-East Asia. These initiatives often prioritize vaccine research and development, resulting in increased funding and support for malaria vaccine projects.

The current report Scope analyzes Malaria Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Malaria Vaccine

According to Cognitive Market Research, the global Malaria Vaccine market size was estimated at USD 1925.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 770.0 million in 2024 and will grow at a compound annual growth rate (CAGR) of 32.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Malaria Vaccine market with a market size of USD 607.59 million in 2024 and is projected to grow at a CAGR of 32.2% during the forecast period. In the U.S., the demand for the Malaria Vaccine market is driven by the increasing awareness of malaria's impact on global health.
• The Canada Malaria Vaccine market had a market share of USD 92.41 million in 2024 and is projected to grow at a CAGR of 33.2% during the forecast period. In Canada, the demand for the Malaria Vaccine market is driven by the rising cases of imported malaria among travelers.
• The Mexico Malaria Vaccine market is projected to witness growth at a CAGR of 32.9% during the forecast period, with a market size of USD 70.08 million in 2024.

Europe Malaria Vaccine

According to Cognitive Market Research, the global Malaria Vaccine market size was estimated at USD 1925.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 577.5 million in 2024 and will grow at a compound annual growth rate (CAGR) of 32.7% from 2024 to 2031.

• The United Kingdom Malaria Vaccine market had a market share of USD 97.03 million in 2024 and is projected to grow at a CAGR of 33.5% during the forecast period. In the UK, the demand for the Malaria Vaccine Market is driven by the increased travel to endemic regions, resulting in a higher incidence of imported malaria cases.
• The France Malaria Vaccine market is projected to witness growth at a CAGR of 31.9% during the forecast period, with a market size of USD 53.14 million in 2024.
• According to Cognitive Market Research, the German Malaria Vaccine market size was valued at USD 114.36 million in 2024 and is projected to grow at a CAGR of 32.9% during the forecast period. In Germany, the demand for the Malaria Vaccine Market is driven by the country’s robust pharmaceutical industry and investments in research and development.
• The Italy Malaria Vaccine market is projected to witness growth at a CAGR of 32.1 during the forecast period, with a market size of USD 49.67 million in 2024.
• The Russia Malaria Vaccine market is projected to witness growth at a CAGR of 31.7% during the forecast period, with a market size of USD 89.52 million in 2024.
• The Spain Malaria Vaccine market is projected to witness growth at a CAGR of 31.8% during the forecast period with a market size of USD 47.36 million in 2024
• The Luxembourg Malaria Vaccine market is projected to witness growth at a CAGR of 32.8% during the forecast period, with a market size of USD 17.90 million in 2024.
• The Portugal Malaria Vaccine market is projected to witness growth at a CAGR of 32.5% during the forecast period, with a market size of USD 12.13 million in 2024.
• The Greece Malaria Vaccine market is projected to witness growth at a CAGR of 33.0% during the forecast period, with a market size of USD 6.93 million in 2024.
• The Rest of Europe's Malaria Vaccine market is projected to witness growth at a CAGR of 31.4% during the forecast period, with a market size of USD 89.52 million in 2024.

Asia Pacific Malaria Vaccine

According to Cognitive Market Research, the global Malaria Vaccine market size was estimated at USD 1925.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 442.8 million in 2024 and will grow at a compound annual growth rate (CAGR) of 36.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Malaria Vaccine market size was valued at USD 199.26 million in 2024 and is projected to grow at a CAGR of 35.7% during the forecast period. In China, the demand for the Malaria Vaccine market is driven by the increasing movement of people between endemic and non-endemic areas has raised awareness about malaria risks, further fueling the need for effective vaccines.
• The Japan Malaria Vaccine market is projected to witness growth at a CAGR of 34.7% during the forecast period, with a market size of USD 61.11 million in 2024.
• The India Malaria Vaccine market had a market share of USD 53.14 million in 2024 and is projected to grow at a CAGR of 38.0% during the forecast period. India's high burden of malaria cases, particularly in rural areas, and the government's commitment to achieving Sustainable Development Goals related to health, driving the market.
• The South Korean Malaria Vaccine market is projected to witness growth at a CAGR of 35.3% during the forecast period, with a market size of USD 44.28 million in 2024.
• The Australian Malaria Vaccine market is projected to witness growth at a CAGR of 35.9% during the forecast period, with a market size of USD 23.03 million in 2024.
• The South East Asia Malaria Vaccine market is projected to witness growth at a CAGR of 37.2% during the forecast period, with a market size of USD 30.55 million in 2024.
• The Rest of Asia Pacific Malaria Vaccine market is projected to witness growth at a CAGR of 36.0% during the forecast period, with a market size of USD 31.44 million in 2024.

South America Malaria Vaccine

According to Cognitive Market Research, the global Malaria Vaccine market size was estimated at USD 1925.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 96.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 33.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Malaria Vaccine market size was valued at USD 41.20 million in 2024 and is projected to grow at a CAGR of 34.2% during the forecast period. In Brazil, the demand for the Malaria Vaccine market is driven by the Increased public awareness of malaria's impact and the urgent need for effective vaccination.
• Argentina's Malaria Vaccine market had a market share of USD 16.17 million in 2024 and is projected to grow at a CAGR of 34.5% during the forecast period. In Argentina, the demand for the Malaria Vaccine market is driven by the ongoing public health campaigns to address the resurgence of malaria in specific areas.
• Colombia’s Malaria Vaccine market is projected to witness growth at a CAGR of 33.4% during the forecast period, with a market size of USD 8.57 million in 2024.
• Peru’s Malaria Vaccine market is projected to witness growth at a CAGR of 33.8% during the forecast period, with a market size of USD 7.89 million in 2024.
• Chile's Malaria Vaccine market is projected to witness growth at a CAGR of 33.9% during the forecast period, with a market size of USD 6.93 million in 2024.
• The Rest of Latin America's Malaria Vaccine market is projected to witness growth at a CAGR of 32.7% during the forecast period, with a market size of USD 15.50 million in 2024.

Middle East Malaria Vaccine

According to Cognitive Market Research, the global Malaria Vaccine market size was estimated at USD 1925.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 38.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 33.9% from 2024 to 2031.

• The GCC Countries Malaria Vaccine market is projected to witness growth at a CAGR of 34.7% during the forecast period, with a market size of USD 16.48 million in 2024. Malaria Vaccine sales flourish due to the increasing number of expatriates and travelers returning from malaria-endemic regions, necessitating effective vaccination strategies to protect public health.
• The Egypt Malaria Vaccine market is projected to witness growth at a CAGR of 34.2% during the forecast period, with a market size of USD 4.04 million in 2024.
• The South Africa Malaria Vaccine market is projected to witness growth at a CAGR of 34.9% during the forecast period, with a market size of USD 6.08 million in 2024. In South Africa, the demand for the Malaria Vaccine Market is driven by the growing recognition of malaria's impact on healthcare costs and productivity.
• The Turkey Malaria Vaccine market is projected to witness growth at a CAGR of 33.4% during the forecast period, with a market size of USD 3.31 million in 2024.
• The Nigeria Malaria Vaccine market is projected to witness growth at a CAGR of 33.0% during the forecast period, with a market size of USD 4.04 million in 2024.
• The Rest of the MEA Malaria Vaccine market is projected to witness growth at a CAGR of 32.9% during the forecast period, with a market size of USD 4.54 million in 2024.

Malaria Vaccine Market Analysis

Malaria Vaccine Market Agent Segment Analysis

According to Cognitive Market Research, Plasmodium Falciparum Malaria will likely dominate the Malaria Vaccine Market over the forecast period. Plasmodium falciparum is responsible for the most severe form of malaria and accounts for the majority of malaria-related morbidity and mortality globally. According to the World Health Organization (WHO), P. falciparum accounted for approximately 99% of malaria cases in Africa and a significant proportion in Southeast Asia, making it a primary target for vaccine development. This agent primarily affects children and pregnant women, leading to severe complications and higher mortality rates. The urgency to protect these vulnerable groups drives the demand for effective vaccines targeting P. falciparum.

Anopheles Species is the fastest-growing segment in the Malaria Vaccine Market. Anopheles mosquitoes are the primary vectors responsible for transmitting malaria parasites, including Plasmodium falciparum and Plasmodium vivax. Understanding their biology and behavior is crucial for developing effective vaccination strategies that can reduce malaria transmission. There is a growing emphasis on integrated vector management strategies that combine various control measures, including vaccines targeting the Anopheles mosquito. Vaccination strategies that focus on reducing the infectivity of mosquitoes can complement existing vector control methods.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Malaria Vaccine Industry. Request a Free Sample PDF!

Malaria Vaccine Market Vaccine Type Segment Analysis

According to Cognitive Market Research, The Pre-Erythrocytic segment holds the largest market share. Pre-erythrocytic vaccines are designed to target the malaria parasite during its pre-erythrocytic stage, specifically the liver stage after infection but before the parasites enter the bloodstream. By inducing an immune response against the sporozoite stage of the Plasmodium parasite, these vaccines aim to prevent the initial infection and subsequent development of malaria.

In the Malaria Vaccine market, the rapidly growing sector is the multi-antigen category. Multi-antigen vaccines are designed to target various stages of the malaria parasite's life cycle, including the sporozoite, liver, and blood stages. By incorporating multiple antigens, these vaccines can elicit a more robust and versatile immune response, making it more difficult for the parasite to evade the immune system.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Malaria Vaccine Route of Administration Segment Analysis

Malaria Vaccine Market Route of Administration Segment Analysis

According to Cognitive Market Research, The Intramuscular Route of Administration segment holds the largest market share. The intramuscular route has a long-standing history of effectively delivering various vaccines, including those for diseases such as hepatitis and influenza. The successful use of IM vaccines in large-scale immunization programs has established a strong foundation for their continued use in malaria vaccination. Extensive data on the safety of intramuscular vaccinations provides confidence to healthcare providers and patients. This familiarity contributes to increased acceptance and willingness to utilize IM-administered malaria vaccines.

In the Malaria Vaccine market, the rapidly growing sector is the Subcutaneous category. Subcutaneous vaccines can exhibit better stability than other routes, especially when formulated with specific stabilizers. This increased stability can enhance the shelf life of the vaccines, reducing wastage and making them more practical for use in low-resource settings. The subcutaneous route is generally perceived as less invasive than the intramuscular route. This can lead to higher acceptance among patients, especially in populations that may be anxious about injections. The use of smaller needles can further reduce discomfort, making it more appealing for vulnerable populations, including children.

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Malaria Vaccine End-Users Segment Analysis

Malaria Vaccine Market End-Users Segment Analysis

According to Cognitive Market Research, The hospital end-users segment holds the largest market share. The rising prevalence of malaria, especially severe cases that require hospitalization, has increased the focus on vaccination as a preventive measure. Hospitals are pivotal in implementing vaccination programs and ensuring access to malaria vaccines for at-risk populations. Many countries, particularly in endemic regions, are investing in healthcare infrastructure to combat malaria more effectively. Improved facilities and resources in hospitals allow for better vaccine storage, handling, and administration, fostering a conducive environment for malaria vaccine implementation.

In the Malaria Vaccine market, the rapidly growing sector is the Specialty Clinics category. Specialty clinics are designed to provide targeted care for specific diseases, including malaria. Their focus on treating complex cases allows them to offer personalized vaccination strategies, making them attractive options for patients seeking specialized care for malaria prevention. Many specialty clinics employ healthcare professionals with expertise in tropical diseases, including malaria. This specialized knowledge enhances the quality of care, making these clinics preferable for patients needing vaccinations and information on malaria prevention.

• Hospitals
• Specialty Clinics
• Homecare
• Others

Malaria Vaccine Distribution Channel Segment Analysis

Malaria Vaccine Market Distribution Channel Segment Analysis

According to Cognitive Market Research, The Hospital Pharmacy Distribution Channel segment holds the largest market share. Hospitals serve as centralized healthcare facilities that offer a wide range of services, including diagnostics, treatment, and preventive care. This integrated approach facilitates the administration of malaria vaccines within the context of overall patient management, particularly for those diagnosed with malaria or at high risk. Patients seeking treatment for malaria-related symptoms or preventive care can easily access vaccines during their visits to hospitals, making hospital pharmacies a convenient choice for vaccination.

In the Malaria Vaccine market, the rapidly growing sector is the Retail Pharmacy Distribution Channel category. There has been a rise in public health campaigns aimed at raising awareness about malaria, its risks, and the importance of vaccination. These campaigns often encourage individuals to seek vaccinations at local pharmacies, increasing foot traffic and demand for malaria vaccines. Retail pharmacies are often more geographically accessible than hospitals, making it easier for individuals to obtain vaccines. The convenience of being able to get vaccinated in a familiar neighborhood setting encourages more people to utilize these services.

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion